Multicenter Validation of Association Between Decline in MRI‐PDFF and Histologic Response in NASH

Emerging data from a single‐center study suggests that a 30% relative reduction in liver fat content as assessed by magnetic resonance imaging–proton density fat fraction (MRI‐PDFF) from baseline may be associated with histologic improvement in nonalcoholic steatohepatitis (NASH). There are limited multicenter data comparing an active drug versus placebo on the association between the quantity of liver fat reduction assessed by MRI‐PDFF and histologic response in NASH. This study aims to examine the association between 30% relative reduction in MRI‐PDFF and histologic response in obeticholic acid (OCA) versus placebo‐treated patients in the FLINT (farnesoid X receptor ligand obeticholic acid in NASH trial).

[1]  B. Neuschwander‐Tetri,et al.  Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial , 2019, The Lancet.

[2]  M. Gorrell.  Faculty Opinions recommendation of Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[3]  Rohit Loomba,et al.  Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. , 2019, Gastroenterology.

[4]  B. Neuschwander‐Tetri,et al.  Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. , 2019, Gastroenterology.

[5]  B. Neuschwander‐Tetri,et al.  Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial , 2018, The Lancet.

[6]  C. Sirlin,et al.  Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. , 2019, Journal of hepatology.

[7]  T. Therneau,et al.  The Role of Three‐Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery , 2020, Hepatology.

[8]  C. Sirlin,et al.  Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. , 2018, Gastroenterology.

[9]  Rohit Loomba,et al.  Noninvasive, Quantitative Assessment of Liver Fat by MRI‐PDFF as an Endpoint in NASH Trials , 2018, Hepatology.

[10]  B. Neuschwander‐Tetri,et al.  Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis , 2018, Hepatology.

[11]  C. Sirlin,et al.  Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis , 2018, Hepatology.

[12]  J. Trotter,et al.  NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial , 2018, The Lancet.

[13]  E. Tapper,et al.  Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD , 2018, Nature Reviews Gastroenterology & Hepatology.

[14]  M. Konerman,et al.  Pharmacotherapy for NASH: Current and emerging. , 2018, Journal of hepatology.

[15]  R. Loomba.  Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions. , 2018, Journal of hepatology.

[16]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[17]  B. Neuschwander‐Tetri,et al.  Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis , 2017, Hepatology.

[18]  N. Obuchowski,et al.  Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis. , 2017, Radiology.

[19]  Z. Goodman,et al.  The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial , 2017, Hepatology.

[20]  Rohit Loomba,et al.  Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. , 2017, Gastroenterology.

[21]  V. Wong,et al.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.

[22]  D. Goldfarb.  National Institute of Diabetes and Digestive and Kidney Diseases ( NIDDK ) Urinary Stone Disease : Research Challenges and Opportunities , 2017 .

[23]  Rohit Loomba,et al.  MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. , 2016, Journal of hepatology.

[24]  D. Brenner,et al.  Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. , 2016, Journal of hepatology.

[25]  C. Sirlin,et al.  Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis , 2016, Therapeutic advances in gastroenterology.

[26]  R. Loomba,et al.  Promising therapies for treatment of nonalcoholic steatohepatitis , 2016, Expert opinion on emerging drugs.

[27]  B. Neuschwander‐Tetri,et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.

[28]  C. Sirlin,et al.  Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  D. Brenner,et al.  Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial) , 2015, Hepatology.

[30]  Rohit Loomba,et al.  Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials , 2013, Hepatology.

[31]  M. Abraham,et al.  Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis , 2012, Hepatology.

[32]  D. Brenner,et al.  Effect of Colesevelam on Liver Fat Quantified by Magnetic Resonance in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial , 2012, Hepatology.

[33]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[34]  Enzo Bonora,et al.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.

[35]  R. Nelson,et al.  Liver biopsy , 2009, Hepatology.

[36]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.